Antigen-specific T-cells are highly variable, spanning potent antiviral efficacy and damaging auto-reactivity. In virus infections, identifying the most efficacious responses is critical to vaccine design. However, current methods depend on indirect measures or on ex vivo expanded CTL clones. We here describe a novel application of cytotoxic saporin-conjugated tetramers to kill antigen-specific T-cells without significant off-target effects. The relative efficacy of distinct antiviral CD8+ T-cell specificity can be directly assessed via antigen-specific CD8+ T-cell depletion. The utility of these reagents is demonstrated here in identifying the CD8+ T-cell specificity most effective in preventing HIV progression in HIV-infected HLA-B*27-positive immune controllers.
Introduction
The notion of selective T-cell depletion, most frequently aiming to purge autoreactivity, has recently gained substantial traction in the immunological field [1] [2] [3] [4] [5] [6] [7] [8] . The development of fluorescently-labeled tetrameric peptide-MHC complexes (tetramers) allowed binding and visualisation of antigen-specific T-cells [9] [10] [11] and has led to the generation of modified tetramers that are coupled to a toxin, such as a ribosome inactivating protein saporin (SAP) , that can selectively kill antigen-specific cells of interest. Being highly specific for their cognate T-cells and rapidly internalised upon engagement of the TCR, peptide-MHC tetramers can deliver any coupled moiety in a very selective manner [12] . The potential to cause death of selected a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 target cells makes SAP-conjugated tetramers (tet-SAP) a powerful tool not only to eliminate auto-reactive T-cells causing disease but also by which to identify antiviral T-cell specificities that are effective in preventing disease [4] .
An elegant proof-of-concept study in the mouse-LCMV model exploited the idea of SAPconjugated tetramers and demonstrated tetramer-mediated selective depletion of certain CD8 + T-cells in vitro and in vivo [4] . These cytotoxic tetramers were later used in vivo in further murine studies to delete diabetogenic T-cells [6] , encephalopathogenic T-cells [5] , minor histocompatibility HY-specific T-cells to prevent organ rejection [7] , or to study 'memory inflation' [13] .
To date, however, the tet-SAP technology has not been applied in human studies. We here set out to demonstrate that this tool can be used to selectively deplete HIV-specific CD8+ Tcells in vitro, and thereby to evaluate the contribution and efficacy of a particular CD8+ T-cell specificity to viral inhibition. Although the importance of CD8+ T-cells in HIV control has been established for some decades [14, 15] , a long-standing question-and one that is critical to HIV vaccine design-remains, namely, which of the many different HIV-specific responses are effective in mediating effective and durable immune control of HIV infection.
Materials and methods

Study subjects
Specimens from adult subjects from the following cohorts were used in our study:
1. Thames Valley cohort [16] : chronically HIV-infected ART-naïve adults were recruited from the Royal Berkshire Hospital, Reading, UK; Northampton General Hospital, Northampton, UK; Churchill Hospital, Oxford, UK; and Wycombe Hospital, High Wycombe, UK. This study was approved by the Institutional Review Board of the University of Oxford and all subjects provided written informed consent for participation in the study.
2. Acute HIV Infection cohort [17, 18] : acutely HIV-infected adults were recruited at the Massachusetts General Hospital, Brigham and Women's Hospital and the Fenway Institute of the Beth Israel Deaconess Medical Center, Boston, MA, USA. Primary infection was classified using Fiebig staging, as previously described [19] . Subject AC198 from this cohort was studied. He is an adult Caucasian male, enrolled in 2005 during early acute infection (estimated 10-15 days post-infection, Fiebig II [19] ) and received six months of ART that was ceased as part of randomly assigned treatment interruption. This study was approved by the Massachusetts General Hospital Institutional Review Board and all subjects provided written informed consent for participation in the study.
3. The Study of the Consequences of Protease Inhibitor Era (SCOPE) cohort [20] : chronically HIV-infected ART-naïve adults recruited at the University of California, San Francisco, USA. This study was approved by the Institutional Review Board of the University of California, San Francisco and all subjects gave written informed consent.
HIV plasma viral load was measured by the Roche Amplicor version 1.5 assay with with COBAS AmpliPrep or TaqMan 48 for the Acute HIV Infection cohort or with COBAS Amplicor for the other cohorts. CD4+ T-cell counts were determined by flow cytometry using standard clinical protocol. CD4+ T-cell counts and viral loads were measured on clinical grounds and the data were supplied by the Centre of Recruitment.HLA typing was performed using a locus specific PCR amplification strategy and a heterozygous DNA sequencing methodology for exon 2 and 3 of the class I PCR amplicon [21] .
Tetramer generation
Peptide-MHC tetramers conjugated to fluorophores were generated as previously described, using streptavidin-PE or APC to tetramerise biotinylated peptide-MHC class I monomers [11] . Efficiency of tetramerisation was confirmed by staining with anti-mouse Ig κ beads (BD Biosciences) with an anti-HLA antibody, followed by tetramer staining. Cytotoxic saporin-conjugated tetramers were produced by the same method using streptavidinsaporin (Advanced Targeting Systems) to tetramerise peptide-MHC monomers according to the published approach [4] . Briefly, these modified tetramers are coupled to a toxin, ribosome-inactivating protein saporin (SAP), that can selectively kill antigen-specific cells of interest and thereby evaluate the contribution of a particular CD8+ T-cell specificity to viral inhibition [4] [5] [6] [7] 13] . Biotinylated peptide-MHC class I monomers generated as per standard published approach [11] were tetramerised by stepwise addition (1/10 th volume every 10 minutes) of streptavidin-SAP (Advanced Targeting Systems) at a 1:1 molar ratio of biotinylated MHC to biotin binding sites [22] . Between additions, tetramerisation reaction was left on a rotor at 4˚C protected from light.
Tetramer staining
For staining with fluorescently-conjugated tetramers, 0. 
Tetramer internalisation experiments
To establish the kinetics of tetramer interactions with human PBMCs, internalisation experiments were performed as previously described [4] . Briefly, cells were incubated with tetramers at 4˚C for 30 minutes to allow binding, further incubated at either 37˚C or 4˚C to promote or inhibit internalisation, respectively, for up to 3 hours, stripped of external fluorescence with 0.5M NaCl/0.5M acetic acid (pH 2.5) and immediately acquired by flow cytometry.
Timecourse of cell-depletion mediated by tetramer-SAP
To establish the timecourse and efficiency of selective tetramer-mediated cell depletion, PBMCs or expanded CD8+ T-cells were treated with tetramer-SAP (5-10 nM) for 2 hours at 37˚C in R10, washed 3 times with R10 and further cultured in R10 (PBMCs) or R10/50
(expanded CD8+ T-cells) [4] . Control treatments included: free SAP, HLA-mismatched tetramer-SAP, tetramer-PE and no treatment. Every 24 hours aliquots of cells from each condition were stained with the relevant fluorochrome-conjugated tetramer and analysed by flow cytometry. For comparison with the conventional cell-depletion method using anti-PE magnetic beads [23] , cells were incubated with tetramer-PE for 30 minutes on ice to allow surface binding and inhibit internalisation; tetramer-PE-bound cells were then removed using anti-PE beads (positive selection) (EasySep, StemCell Technologies) according to the manufacturer's protocol.
Viral inhibition assay
To evaluate the effect of tet-SAP-mediated depletion of epitope-specific CD8+ T-cells on their antiviral capacity, we modified previously described viral inhibition assay [24] as follows. We used HIV-permissive H9 cell line transfected with the HLA-B Ã 27:05 gene (a generous gift from Otto Yang) as targets; controls included H9 cells expressing HLA-B Ã 57:03 or HLA-untransfected. As effector cells, we treated PBMCs with a monoclonal CD3.4 antibody bi-specific for CD3 and CD4 (the NIH AIDS Reagent Program) to eliminate CD4+ T cells and expand CD8+ T-cells [25] [26] [27] . Expanding CD8+ T-cells were cultured for 10-20 days to achieve >90% purity and sufficient numbers. 24-48 hours prior to the inhibition assay, CD8+ T-cells were treated with tet-SAP or a control (untreated, HLA-mismatched tet-SAP, tet-PE, free SAP) as described above. When cell numbers allowed, cell-depletion was confirmed by tetramer staining. For the initial setup of the inhibition assay, target cells were infected with pre-titrated NL4-3-GFP [16] by spinoculation for 1 hour, incubated at 37˚C for 1 hour, repeatedly washed and further cultured with or without effector cells at an appropriate effector to target cell ratio in duplicates or triplicates. Every 2-3 days, the cultures were fed and stained to assess live CD4+ GFP+ cells. % GFP+ uninfected target cells served as a background, subtracted from all values. HIV-suppressive capacity was calculated at the time of the peak of viral growth as follows [24] : suppressive capacity = log 10 (%GFP+ infected target cells without effector cells / %GFP+ target cells with effector cells). Analysis was performed in GraphPad Prism for Mac OSX, 5.0c (GraphPad Software).
ELISPOT assay
Interferon-γ ELISPOT assays were performed as previously described [28, 29] . Peptides were generated by Schafer-N.
Sanger sequencing of proviral genome
Genomic DNA was extracted from PBMCs using QIAmp DNA Mini kit following manufacturer's protocol (Qiagen). Full length HIV genome was amplified in two overlapping fragments, purified and sequenced as previously described [30] . This was confirmed by sequencing of HIV protein-long fragments as previously described [31] . All sequencing was done using BigDye Terminator v3.1 Ready Reaction mix (Applied Biosystems) and analysed using Sequencher v4.8 (Gene Codes Corp.).
Results
Recognition and internalisation of conventional and cytotoxic tetramers
We first confirmed that SAP conjugation to tetramers did not compromise tetramer recognition and internalisation by cognate CD8+ T-cells. Stainings with conventional, fluorescently labelled peptide-MHC tetramers (tet-PE or tet-APC) and with cytotoxic tetramers (tet-SAP) of the same specificity showed comparable levels of responses (S1 Fig (Fig 1B and 1C) . HLA-mismatched tetramers (in this case HLA-B Ã 07:02-specific tetramers) showed low background staining ( 0.03% of CD8+ T-cells), similar to conventional tetramers (Fig 1D and 1E) . Free SAP, not conjugated to tetramers and therefore lacking the means of cell entry, did not show CD8+ T-cell binding or internalisation (Fig 1F) . The kinetics of tetramer binding and internalisation was strongly temperature-dependent (Fig 1G) , consistent with murine studies [4] , and reached maximum within two hours of tetramer-PBMC incubation at 37˚C.
Tet-SAP effectively and specifically depletes cognate CD8+ T-cells
We next assessed whether cytotoxic tetramers could deplete specific populations of human CD8+ T-cells. An illustrative example in Fig 2A, involving the same HLA-B Ã 27:05-KK10 tetramers, shows staining of PBMCs with conventional KK10-PE tetramers following either no treatment, or treatment with KK10-SAP tetramer, HLA-mismatched tetramer or free SAP. This demonstrated that, by 24 hours post-treatment, nearly all KK10-specific cells had been depleted by tet-SAP, and did not re-emerge later in the time course (up to 72hrs). Similar observations were made in relation to four other SAP-conjugated tetramers, to represent a range of different HLA class I types and to include CD8+ T-cell responses to CMV and EBV in addition to HIV (Fig 2B) .
To address the possibility that tetramer-mediated depletion of CD8+ T-cells of one specificity has any off-target effects on other CD8+ T-cell specificities, in particular those restricted by the same HLA class I molecule, we studied the impact of the HLA-B Ã 27:05-KK10 tet-SAP on CD8+ T-cells recognising the HLA-B Ã 27:05-restricted, subdominant HIV Pol epitope KY9 (   901   KRKGGIGGY   909 ) [16] . Treatment with KK10-SAP resulted in effective depletion of KK10-specific cells, but did not affect KY9-specific cells (Fig 2C and 2D) . Similarly, KY9-SAPmediated depletion of KY9-specific cells did not have an effect on KK10-specific cells. These data underscore the high degree of specificity maintained by the cytotoxic tetramers.
Contribution of KK10 to immune control of HIV determined by tet-SAP
We next applied cytotoxic tetramers to determine the contribution of specific CD8+ T-cell responses to immune control of viral infections such as HIV. To evaluate the contribution of the HLA-B Ã 27:05-KK10 response in an HIV-infected HLA-B Ã 27:05-positive subject, we nonspecifically expanded 'bulk' CD8+ T-cells from PBMCs using the bi-specific monoclonal CD3.4 antibody [25] [26] [27] , and then treated them with either the KK10-tet-SAP or treatments that did not affect the HLA-B Ã 27:05-KK10 CD8+ T-cells (no treatment, treatment with KK10-PE tetramer or with an HLA-mismatched tet-SAP; Fig 3A) . We then assessed inhibition of HIV replication in HLA-B Ã 27:05-expressing target cells by CD8+ T-cells with or without Gag-KK10 depletion. The example in Fig 3B and 3C illustrates that the CD8+ T-cells with unaffected HLA-B Ã 27:05-KK10-specific cells inhibited viral replication by 3-4 log 10 compared to the KK10-depleted CD8+ T-cells that lost the inhibitory capacity. Of note, treatment with KK10-PE tetramer resulted in a lower percentage of KK10-specific cells being detectable by tetramer staining 48 hours following the treatment, which was likely caused by the transient loss of their capacity to efficiently bind tetramers-a normal characteristic of CD8+ T-cell activation [32] . Importantly, however, KK10-PE treatment did not impact T-cell suppressive capacity, whereas KK10-SAP treatment substantially reduced viral inhibition (Fig 3B and 3C) . These results strongly suggest that the KK10-specific cells had indeed been depleted by the cytotoxic KK10-SAP rather than become refractory to tetramer-PE binding and thus undetectable by tetramer staining. Additionally, as we demonstrated earlier, the potent toxic tetramer had been internalised (Fig 1) and no rebound KK10-specific T-cell population re-emerged for up to 72 hours post-treatment (Fig 2A and 2B) .
In a separate experiment, we ran the same tet-SAP depletion procedure in parallel with depletion using anti-PE magnetic beads [23] (Fig 3D-3F ). This showed that depletion efficiency and loss of viral inhibition were similar irrespective of the method of depletion (see Discussion below). Definition of antiviral efficacy of different CD8+ T-cell responses using tet-SAP We next employed the tet-SAP reagents to compare simultaneously HIV-suppressive capacity of several CD8+ T-cell specificities following this approach ( S2 Fig). We used samples from an HLA-B Ã 27:05-positive HIV-infected donor who initially controlled viraemia and had three wildtype HLA-B Ã 27-restricted dominant responses, as determined by IFN-γ ELISPOT assays and confirmed by tetramer staining (Fig 4A-4C) : Gag-KK10, Pol-KY9 and Vpr-VL9 ( Responses to the wild-type epitopes diminished over time, while viraemia progressively increased and well-characterised HLA-B Ã 27-associated mutations emerged in the dominant responses ( Fig  4D) . Viral sequence encoding the Vpr epitope was not available for the earliest timepoint, but the R32K escape mutant present at months 39 and 78 is characteristically selected specifically in HLA-B Ã 27-positive subjects [33] . We next evaluated the impact on viral inhibition of tet-SAP-mediated depletion of CD8+ T-cell responses present, studying two timepoints, 4 and 8 years after infection. At 4 years (48 months) post-infection, Pol-KY9 and Vpr-VL9 depletion made little difference to viral replication, while Gag-KK10 depletion significantly attenuated the ability of CD8+ T-cells to suppress viral replication, suggesting that the majority of bulk CD8+ T-cell-mediated inhibition was Gag-KK10-specific (Fig 4E-4G) . At 8 years (96 months) post-infection (Fig 4H-4J) , the contribution of the Pol-KY9 response to inhibition of viral replication was lost altogether; Vpr-VL9 continued not to contribute significantly to viral inhibition, and the Gag-KK10-specific cells contributed the most. Of note, the Gag-KK10 effect was seen with both the wild-type-specific and mutant L268M-specific tet-SAP mediated depletion (Fig 4G and 4J ). This can be explained by cross-recognition of the variant by the wild-type-specific cells that are highly effective against both wild-type and L268M viruses, express an anti-apoptotic phenotype and are long-lived. [34, 35] Although in this case the subject initiated ART through choice after 9 years of infection, viral load was well contained for much of this time at <2,000 copies/ml, and absolute CD4 counts were maintained at high levels of 500-700 cells/mm 3 until ART intervention. This is representative of 2 similar experiments involving HLA-B Ã 27:05-positive HIV-infected individuals, showing that in subjects with low viral loads (e.g. 73 copies/ml, 518 copies/ml), inhibition of viral replication was highly dependent upon the Gag-KK10 response ( S3 Fig). 
Discussion
In summary, we here show, for the first time, that cytotoxic saporin-conjugated tetramers can be used in in vitro studies with human cells. These tetramers bind and are internalised by cognate CD8+ T-cells, resulting in their effective elimination by as little as 24 hours. We did not observe an off-target effect and found that the tet-SAP approach is considerably simpler and less time-consuming than the conventional method using magnetic beads, especially if more than one CD8+ T-cell specificity is being assessed. These reagents can facilitate identification of effective HIV-specific CD8+ T-cell responses that could be induced by a successful vaccine, and can also be used in other viral infections such as CMV or HCV. Finally, as shown in murine studies [4] , saporin-conjugated tetramers have the potential for in vivo depletions to be undertaken immunotherapeutically in humans. 
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